Reglutide 1.34 mg/ml (SC Injection)
3 ml cartridge with device: ৳ 5,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Semaglutide |
| Company | Beximco pharmaceuticals ltd |
Indications
- Adjunct to diet and exercise for type 2 diabetes mellitus
- Reduce risk of major adverse cardiovascular events in type 2 diabetes
- Chronic weight management for obesity
- Usable for overweight patients with weight-related comorbid conditions
- Usable with an initial body mass index (BMI) of 30 kg/m^2 or greater
- Usable with an initial body mass index (BMI) of 27 kg/m^2 or greater
Pharmacology
- GLP-1 analogue
- 94% sequence similarity to human GLP-1
- Acts as a GLP-1 receptor agonist
- Stimulates insulin secretion
- Lowers glucagon secretion
- Reduces blood glucose in a glucose-dependent manner
- Reduces body weight and body fat mass
- Reduces appetite
Dosage & Administration
- Tablet form to be taken at least 30 minutes before the first food or beverage of the day
- Initial dose of 3 mg once daily for 30 days
- Maintenance dose of 7 mg once daily
- Additional glycemic control with 14 mg once daily
- Injection form with starting dose of 0.25 mg once weekly
- Increases to 0.5 mg once weekly after 4 weeks
- Increases to 1 mg once weekly for further glycemic control after at least 4 weeks on 0.5 mg
- Weekly doses higher than 1 mg not recommended
- Administration via subcutaneous injection in the abdomen, thigh, or upper arm
- Change in injection site without dose adjustment
- Compatible for use with or without meals
- Switchable between injection and tablet form
Interaction
- Potential impact on the rate of absorption of concomitantly administered oral medicinal products
- Caution when used with oral medicinal products requiring rapid gastrointestinal absorption
Contraindications
- Hypersensitivity to the active substance or excipients
Side Effects
- Hypoglycemia when used with insulin or sulfonylurea
- Gastrointestinal disorders
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Constipation
- Allergic reactions
- Injection site reactions
- Lipodystrophy
- Pruritus
- Rash
Pregnancy & Lactation
- Not for use during pregnancy
- Discontinue 2 months before planned pregnancy
- Not for use during breastfeeding
Precautions & Warnings
- Not for type 1 diabetes mellitus or treatment of diabetic ketoacidosis
- Discontinue if pancreatitis is suspected
- Monitoring for patients with diabetic retinopathy
Use in Special Populations
- Safety and efficacy in children and adolescents not yet established
- No dose adjustment based on age for elderly patients
- No dose adjustment for mild, moderate, or severe renal impairment
- Not recommended for use in end-stage renal disease
- No dose adjustment for hepatic impairment
- Caution for treating patients with hepatic impairment
Overdose Effects
- Reported overdose up to 4 mg in a single dose and up to 4 mg in a week
- Most commonly reported adverse reaction: nausea
- No specific antidote for overdose
- Supportive treatment for overdose based on clinical signs and symptoms
- Consider dose adjustment when adding to existing metformin and/or thiazolidinedione therapy
- Consider reduction in the dose of sulfonylurea or insulin when adding reglutide
- Self-monitoring of blood glucose for dose adjustment of sulfonylurea and insulin
- Missed dose can be administered within 5 days after the missed dose
Therapeutic Class
- GLP-1 receptor agonists
Storage Conditions
- Store at 2°C to 8°C (in a refrigerator)
- Do not freeze
- Keep out of reach of children